Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (21-30 of 420) with videos related to

Pageof 42
Sort By:
Best Practice & Research. Clinical Haematology|December 4, 2012
Is it time to revisit standard post-remission therapy?Richard M Stone
Expert Review of Hematology|April 4, 2013
Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of HematologyRichard M Stone
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
New therapies in leukemia: renewed hopeRichard M Stone
Seminars in Hematology|September 6, 2002
Treatment of acute myeloid leukemia: state-of-the-art and future directionsRichard M Stone
Best Practice & Research. Clinical Haematology|December 2, 2008
Are new agents really making a difference in MDS?Richard M Stone
Best Practice & Research. Clinical Haematology|December 1, 2011
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?Richard M Stone
Current Hematologic Malignancy Reports|April 29, 2010
The role of molecular tests in acute myelogenous leukemia treatment decisionsGabriela Motyckova, Richard M Stone
Haematologica|November 2, 2018
Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not applyRichard M Stone, Coleman Lindsley
Current Opinion in Hematology|January 9, 2020
Optimal therapeutic strategies for mixed phenotype acute leukemiaOfir Wolach, Richard M Stone
Blood|January 22, 2015
How I treat mixed-phenotype acute leukemiaOfir Wolach, Richard M Stone
Pageof 42

Showing results (21-30 of 420) with videos related to

Sort By:
Pageof 42
Best Practice & Research. Clinical Haematology|December 4, 2012
Is it time to revisit standard post-remission therapy?Richard M Stone
Expert Review of Hematology|April 4, 2013
Highlights in acute myeloid leukemia from the 2012 meeting of the American Society of HematologyRichard M Stone
Journal of Hematotherapy & Stem Cell Research|August 31, 2002
New therapies in leukemia: renewed hopeRichard M Stone
Seminars in Hematology|September 6, 2002
Treatment of acute myeloid leukemia: state-of-the-art and future directionsRichard M Stone
Best Practice & Research. Clinical Haematology|December 2, 2008
Are new agents really making a difference in MDS?Richard M Stone
Best Practice & Research. Clinical Haematology|December 1, 2011
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?Richard M Stone
Current Hematologic Malignancy Reports|April 29, 2010
The role of molecular tests in acute myelogenous leukemia treatment decisionsGabriela Motyckova, Richard M Stone
Haematologica|November 2, 2018
Older adults with acute myeloid leukemia treated with intensive chemotherapy: "old" prognostic algorithms may not applyRichard M Stone, Coleman Lindsley
Current Opinion in Hematology|January 9, 2020
Optimal therapeutic strategies for mixed phenotype acute leukemiaOfir Wolach, Richard M Stone
Blood|January 22, 2015
How I treat mixed-phenotype acute leukemiaOfir Wolach, Richard M Stone
Pageof 42